FDA approves Fusion's sealant for neurosurgical use:
This article was originally published in Clinica
Fusion Medical Technologies' will expand the use of its Proceed haemostatic sealant into neurosurgical and cranial applications. The product can now be targeted for use in around 240,000 neurosurgical/cranial procedures that are performed every year worldwide, says Fusion, of Fremont, California. It will be sold in the spinal and cranial markets by Sulzer Spine-Tech, which estimates that the annual worldwide market for the device in cranial applications is worth $15-20 million.